- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01907867
Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin
An Open-Label Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin After Single and Multiple Doses Administered Orally in Healthy Volunteers
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85006
- Pulmonary Associates, PA
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Able to provide written informed consent;
- Age ≥18 years and ≤55 years;
- Male or female healthy volunteer;
Body mass index (BMI) ≥18.0 kg/m2 and ≤30.0 kg/m2 and a body weight
≥48 kg and ≤100 kg;
Women of childbearing potential must have a negative urine pregnancy test confirmed at Screening before study enrollment, must not be breastfeeding, and must use an effective method of contraception for at least 1 month before enrollment and through 3 months following completion of the study:
- A woman of childbearing potential is defined as any female subject who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal (defined as women over the age of 50 who have been amenorrheic for at least 12 consecutive months);
- Women who are using oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as an intrauterine device or barrier method (diaphragm, condoms, spermicides) to prevent pregnancy, or whose partner is sterile (e.g. vasectomy) should be considered to be of childbearing potential;
- If a male subject's sexual partner is of childbearing potential, the male subject must acknowledge that they are using an acceptable method of contraception (defined above) from the first dose of study drug until 3 months from last dosing occasion to prevent pregnancy;
- Expectation, in the judgment of the Investigator, that the subject will complete all study activities; and
- Willing to comply with all the study activities and procedures throughout the duration of the study.
Exclusion Criteria:
- Known chronic medical conditions, including any respiratory condition such as asthma or chronic obstructive pulmonary disease, or cardiovascular conditions such as hypertension or coronary artery disease;
- Prolongation of corrected QT interval (QTcB) at rest, where the mean QTcB interval is >500 msec based on triplicate ECG at Screening;
- Use of tobacco products within 6 months of Screening;
- Women who are pregnant or breastfeeding;
- Receipt of any investigational medication during the last month (30 days or 5 half-lives, whichever is longer) prior to enrollment;
- Prior exposure to finafloxacin;
- Use of any concomitant medication (including over-the-counter drugs, vitamins, and antacids) within 7 days prior to study drug administration and during the study (acetaminophen is allowed);
- Any disorder that may interfere with the evaluation of study drug;
- Known hypersensitivity to finafloxacin or to any other fluoroquinolone;
- Donated any blood, plasma, or platelets in the 3 months prior to enrollment or on more than 2 occasions within the 12 months preceding the first dose of study drug;
- Known history of tendon rupture or tendonitis;
- A positive urine drug screen or breath alcohol test result at Screening or enrollment;
- Known to have viral hepatitis, or are positive for the Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody, or are positive for Human Immunodeficiency Virus (HIV) antibodies;
- Clinically significant abnormal laboratory values at Screening or enrollment;
- Unable or unwilling, in the judgment of the Investigator, to comply with the protocol;
- An employee of the Investigator or study site with direct involvement in the proposed study or other studies under the direction of the Investigator or study site, or a family member of the site employee or the Investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Cohort 1
Day 1: Finafloxacin 800 mg will be administered as an oral dose once in the morning (first dose). Subjects will have plasma PK samples drawn at specified times around the first dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 3 hours after the oral dose. Day 2: Finafloxacin 800 mg will be administered as an oral dose once in the morning (second dose). Day 3: Finafloxacin 800 mg will be administered as an oral dose once in the morning (third dose). Subjects will have plasma PK samples drawn at specified times around the third dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 6 hours after the oral dose, followed immediately by BAL to obtain alveolar ELF samples. |
|
EXPERIMENTAL: Cohort 2
Day 1: Finafloxacin 800 mg will be administered as an oral dose once in the morning (first dose). Subjects will have plasma PK samples drawn at specified times around the first dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 8 hours after the oral dose. Day 2: Finafloxacin 800 mg will be administered as an oral dose once in the morning (second dose). Day 3: Finafloxacin 800 mg will be administered as an oral dose once in the morning (third dose). Subjects will have plasma PK samples drawn at specified times around the third dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 12 hours after the oral dose, followed immediately by BAL to obtain alveolar ELF samples. |
|
EXPERIMENTAL: Cohort 3
Day 1: Finafloxacin 800 mg will be administered as an oral dose once in the morning (first dose). Subjects will have plasma PK samples drawn at specified times around the first dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 12 hours after the oral dose. Day 2: Finafloxacin 800 mg will be administered as an oral dose once in the morning (second dose). Day 3: Finafloxacin 800 mg will be administered as an oral dose once in the morning (third dose). Subjects will have plasma PK samples drawn at specified times around the third dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 24 hours after the oral dose, followed immediately by BAL to obtain alveolar ELF samples. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess the safety and tolerability of orally administered finafloxacin in healthy subjects.
Time Frame: Day 3
|
The assessment of safety will be based primarily on the frequency of adverse events, clinical laboratory assessments (chemistry, hematology, and urinalysis), physical examinations, vital signs, and 12-lead ECGs.
Other safety data will be summarized as appropriate.
The data will be presented in descriptive manner.
|
Day 3
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic (PK) profile in plasma and epithelial lining fluid (ELF)
Time Frame: Day 3
|
To assess the pharmacokinetic (PK) profile in plasma and epithelial lining fluid (ELF) of finafloxacin after single and multiple doses administered orally in healthy subjects;
|
Day 3
|
Comparison of bronchial ELF PK profiles with alveolar ELF PK profiles.
Time Frame: Day 3
|
To compare the bronchial ELF PK profiles obtained by bronchoscopic microsampling (BMS) techniques to alveolar ELF PK profiles obtained by bronchoalveolar lavage (BAL).
|
Day 3
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intracellular concentrations of finafloxacin in alveolar macrophages (AMs).
Time Frame: Day 3
|
To assess the intracellular concentrations of finafloxacin as measured in alveolar macrophages (AMs) obtained by BAL.
|
Day 3
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mark H. Gottfried, MD, Pulmonary Associates, PA
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FINA-008
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Safety and Tolerability
-
JemincareRecruitingSafety and TolerabilityChina
-
Island PharmaceuticalsBeyond Drug DevelopmentCompletedSafety and TolerabilityAustralia
-
Damian Pharma AGUniversity Hospital Inselspital, Berne; Covance; Foundation for Therapeutic Research...Completed
-
AnaMar ABCovanceCompletedTolerability | SafetyUnited Kingdom
-
Usona InstituteCompletedPharmacokinetics | Tolerability | SafetyUnited States
-
4TEEN4 Pharmaceuticals GmbHRecruitingPhase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics/-Dynamics of AK1967 (Procizumab)Safety and TolerabilityNetherlands
-
Alumis IncCompletedSafety and TolerabilityUnited States
-
Gabather ABSmerud Medical Research International ASCompletedSafety and TolerabilityFinland
-
Modus Therapeutics ABCompletedPlacebo-controlled Study to Determine the Safety and Tolerability of Subcutaneous Doses of SevuparinSafety and TolerabilityUnited States
-
Kowa Research Institute, Inc.CompletedSafety and TolerabilityUnited States
Clinical Trials on Finafloxacin 800 mg (as 4 x 200 mg tablet) once daily for 3 days
-
Federal Budgetary Research Institution State Research...CompletedSmallpox | Monkeypox | Cowpox | Vaccinia Virus InfectionRussian Federation
-
ViiV HealthcareCompletedHIV Infections | Infection, Human Immunodeficiency VirusUnited States
-
Egyptian Liver HospitalWadi El Nil HospitalCompleted
-
Gilead SciencesCompletedHepatitis CUnited States, Puerto Rico
-
Jiuda ZhaoSecond Hospital of Lanzhou UniversityRecruiting
-
ExCellThera inc.Memorial Sloan Kettering Cancer CenterRecruitingCord Blood Transplant | High Risk Myeloid MalignanciesUnited States
-
AstraZenecaQuotient SciencesCompletedCancerUnited Kingdom
-
Tatyasaheb Kore Dental CollegeCompletedCrown Lengthening Procedure With OstectomyIndia
-
All India Institute of Medical Sciences, New DelhiCompleted
-
Memorial Sloan Kettering Cancer CenterBristol-Myers SquibbCompletedLeukemia | Acute Lymphoblastic LeukemiaUnited States